Victoria Smith

Victoria Smith

Company: Amphivena Therapeutics Inc.

Job title: Chief Scientific Officer


AMV564 Depletes MDSC & Activates T Cells in Cancer Patients 1:45 pm

AMV564 is a clinical-stage bivalent T cell engager that selectively targets myeloid derived suppressor cells (MDSC) Subcutaneous injection of AMV564 is well tolerated with early evidence of clinical activity in cancer patients in a phase 1 study Pharmacodynamic data from patients treated with AMV564 demonstrate significant decreases in MDSC in parallel with evidence of CD8…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.